[1] 惠丽娜, 范开席, 徐忠法. 肾细胞癌的治疗方法及应用现状[J]. 山东医药, 2015, 55(14): 102-103.
[2] Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?[J]. Eur Urol, 2010, 58(4): 588-595.
[3] Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review[J]. Cancer Treat Rev, 2008, 34(3): 193-205.
[4] 刘 磊. 转移性肾细胞癌靶向药物治疗的现状[J]. 国际泌尿系统杂志, 2015, 35(6): 923-926.
[5] 吴少花, 陈 君, 刘亚萌, 等. 杨梅素抗肿瘤活性研究进展[J]. 吉林医药学院学报, 2015, 36(5): 381-383.
[6] 刘雪丽, 周学锋, 王君瑜, 等. 中药抗肿瘤作用机制研究进展[J]. 中国药师, 2016, 19(6): 1158-1162.
[7] Feng J, Chen X, Wang Y, et al. Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells[J]. Mol Cell Biochem, 2015, 408(1-2): 163-170.
[8] Huang H, Chen AY, Ye X, et al. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway[J]. Int J Oncol, 2015, 47(4): 1494-1502.
[9] Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo[J]. Nutr Cancer, 2012, 64(4): 599-606.
[10] Seydi E, Rasekh HR, Salimi A, et al. Myricetin selectively induces apoptosis on cancerous hepatocytes by directly targeting their mitochondria[J]. Basic Clin Pharmacol Toxicol, 2016, 119(3): 249-258.
[11] 郭海清, 任 锋, 陈亚利, 等. 杨梅素对HepG2细胞凋亡的影响[J]. 北京医学, 2014, 36(9): 748-751,799.
[12] 李有富, 李魏林. 杨梅素对肝癌细胞Bel-7402裸鼠移植瘤的抑制作用[J]. 中国医药导报, 2015, 12(31): 44-47.
[13] 李有富, 李 辉, 韩 涛, 等. 杨梅素诱导人宫颈癌HeLa细胞凋亡及凋亡通路的研究[J]. 西北药学杂志, 2016, 31(3): 270-274.
[14] 刘师兵, 陈 君, 吴少花, 等. 杨梅素诱导HeLa细胞凋亡的形态学研究[J]. 吉林医药学院学报, 2015, 36(6): 418-421.
[15] Shih YW, Wu PF, Lee YC, et al. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway[J]. J Agric Food Chem, 2009, 57(9): 3490-3499.